Wells Fargo
NAVB

Wells Fargo’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Wells Fargo’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,632
Closed -$504 – 7862
2023
Q3 		$504 Buy
5,632
+140
+3% +$13 ﹤0.01% 6363
2023
Q2 		$505 Buy
5,492
+21
+0.4% +$3 ﹤0.01% 6486
2023
Q1 		$1.42K Sell
5,471
-1,829
-25% -$534 ﹤0.01% 6292
2022
Q4 		$1.53K Buy
7,300
+2,345
+47% +$586 ﹤0.01% 6072
2022
Q3 		$1K Buy
4,955
+1
+0% – ﹤0.01% 6564
2022
Q2 		$3K Sell
4,954
-13
-0.3% -$11 ﹤0.01% 6273
2022
Q1 		$4K Sell
4,967
-19
-0.4% -$17 ﹤0.01% 6561
2021
Q4 		$5K Hold
4,986
– – ﹤0.01% 6728
2021
Q3 		$8K Buy
4,986
+12
+0.2% +$20 ﹤0.01% 6290
2021
Q2 		$9K Buy
4,974
+3
+0.1% +$5 ﹤0.01% 6195
2021
Q1 		$10K Buy
4,971
+30
+0.6% +$70 ﹤0.01% 6363
2020
Q4 		$10K Sell
4,941
-820
-14% -$1.93K ﹤0.01% 6037
2020
Q3 		$15K Buy
5,761
+884
+18% +$3.17K ﹤0.01% 5823
2020
Q2 		$20K Sell
4,877
-3,053
-38% -$5.84K ﹤0.01% 5704
2020
Q1 		$6K Buy
7,930
+136
+2% +$150 ﹤0.01% 5848
2019
Q4 		$10K Hold
7,794
– – ﹤0.01% 5906
2019
Q3 		$5K Buy
7,794
+1,000
+15% +$615 ﹤0.01% 6091
2019
Q2 		$4K Buy
6,794
+1,973
+41% +$3.83K ﹤0.01% 6095
2019
Q1 		$13K Hold
4,821
– – ﹤0.01% 5605
2018
Q4 		$10K Hold
4,821
– – ﹤0.01% 5943
2018
Q3 		$22K Buy
4,821
+15
+0.3% +$57 ﹤0.01% 5814
2018
Q2 		$22K Sell
4,806
-4,117
-46% -$21.5K ﹤0.01% 5800
2018
Q1 		$65K Sell
8,923
-695
-7% -$5.2K ﹤0.01% 5477
2017
Q4 		$69K Buy
9,618
+4,796
+99% +$40.6K ﹤0.01% 5442
2017
Q3 		$40K Buy
4,822
+2,822
+141% +$23.9K ﹤0.01% 5540
2017
Q2 		$20K Sell
2,000
-50
-2% -$494 ﹤0.01% 5633
2017
Q1 		$24K Sell
2,050
-470
-19% -$5.34K ﹤0.01% 5669
2016
Q4 		$32K Sell
2,520
-32
-1% -$508 ﹤0.01% 5510
2016
Q3 		$47K Sell
2,552
-1,975
-44% -$25K ﹤0.01% 5326
2016
Q2 		$48K Buy
4,527
+716
+19% +$14.1K ﹤0.01% 5216
2016
Q1 		$73K Buy
3,811
+399
+12% +$7.68K ﹤0.01% 5056
2015
Q4 		$91K Sell
3,412
-148
-4% -$5.14K ﹤0.01% 4982
2015
Q3 		$162K Sell
3,560
-179
-5% -$6.75K ﹤0.01% 4583
2015
Q2 		$121K Buy
3,739
+2,298
+159% +$66.8K ﹤0.01% 4933
2015
Q1 		$45K Buy
1,441
+41
+3% +$1.39K ﹤0.01% 5058
2014
Q4 		$53K Buy
1,400
+423
+43% +$11.6K ﹤0.01% 4995
2014
Q3 		$26K Sell
977
-164
-14% -$4.34K ﹤0.01% 5192
2014
Q2 		$34K Buy
1,141
+586
+106% +$19K ﹤0.01% 5121
2014
Q1 		$21K Buy
555
+15
+3% +$569 ﹤0.01% 5214
2013
Q4 		$23K Sell
540
-260
-33% -$10.2K ﹤0.01% 4985
2013
Q3 		$43K Buy
800
+145
+22% +$8.45K ﹤0.01% 4722
2013
Q2 		$35K Buy
+655
New +$32.7K ﹤0.01% 4703

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Wells Fargo's NAVB Position: Q4 2023 in Review

Wells Fargo sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 5,632 shares — an estimated $504 sold.

Wells Fargo first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $162K in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Wells Fargo reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 5,632 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $504.
  • Wells Fargo first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
  • Wells Fargo's Navidea Biopharmaceuticals Inc. position peaked at $162K in Q3 2015.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.